 Treatment-related serious adverse events CTCAE grade 3 or higher were anemia, leukopenia, thrombocytopenia, mucositis and liver decompensation, and their rates were 2.5, 2.4-5.0, 17.5, 10 and 7.3-17.5, respectively. In addition, 2.4-5.0 of adverse events were chemoport-related adverse events including infection and port obstruction. 